Gapping up
News:
- RFP +65.7% (entered into an agreement under which Domtar will acquire all of the outstanding common shares of Resolute stock for $20.50 per share and one Contingent Value Right)
- AMTI +2.9% (to report top-line Phase 2 results from MARKET combination Trial of Oral AMT-101)
- PRIM +2.1% (awarded a $170 mln project by Texas DOT)
- BIIB +2.1% (Biogen and Eisai receives BLA acceptance and Priority Review from FDA for Lecanemab)
- EPM +2% (CEO to step down)
- MO +2% (FDA administratively stayed the marketing denial order; determined that there are scientific issues unique to the JUUL application that warrant additional review)
- BOC +1.8% (acquires the internet service assets of Strawberry Comms)
- FTI +1.6% (to conduct iFEED study for Equinor)
- LSI +1.6% (increases dividend)
- VORB +1.5% (entered into a securities purchase agreement pursuant to which the Company sold and issued convertible debenture on June 29, 2022 in the principal amount of $50.0 mln)
- CMBM +1.5% (delivers initial order of Microwave Line-of-Sight radios to Advanced Technology Systems Company)
- JKS +1.1% (authorizes the Company to repurchase up to $200 million of its ordinary shares represented by ADSs during an 18-month period)
- SRPT +1% (to share new clinical data and analysis for SRP-9001)
- ISEE +1% (IVERIC bio and DelSiTech enter exclusive agreement for development of sustained release Zimura)
- VERU +1% (New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients)
Analyst comments:
- CDEV +3.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- AOS +1.2% (upgraded to Buy from Neutral at Longbow)